Cassava Sciences (SAVA) Competitors $2.25 +0.07 (+3.21%) Closing price 04:00 PM EasternExtended Trading$2.24 -0.01 (-0.62%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. KOD, KMDA, ERAS, CGEM, CMPS, PRTA, TECX, PRTC, CYRX, and GOSSShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Kodiak Sciences (KOD), Kamada (KMDA), Erasca (ERAS), Cullinan Therapeutics (CGEM), COMPASS Pathways (CMPS), Prothena (PRTA), Tectonic Therapeutic (TECX), PureTech Health (PRTC), CryoPort (CYRX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Its Competitors Kodiak Sciences Kamada Erasca Cullinan Therapeutics COMPASS Pathways Prothena Tectonic Therapeutic PureTech Health CryoPort Gossamer Bio Kodiak Sciences (NASDAQ:KOD) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Does the media refer more to KOD or SAVA? In the previous week, Kodiak Sciences and Kodiak Sciences both had 4 articles in the media. Kodiak Sciences' average media sentiment score of 0.87 beat Cassava Sciences' score of 0.28 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in KOD or SAVA? 89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by insiders. Comparatively, 12.2% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer KOD or SAVA? Kodiak Sciences currently has a consensus target price of $9.00, suggesting a potential upside of 12.08%. Cassava Sciences has a consensus target price of $2.00, suggesting a potential downside of 11.11%. Given Kodiak Sciences' higher probable upside, equities analysts clearly believe Kodiak Sciences is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, KOD or SAVA? Kodiak Sciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -2.05, suggesting that its share price is 305% less volatile than the S&P 500. Which has better earnings and valuation, KOD or SAVA? Kodiak Sciences is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKodiak SciencesN/AN/A-$176.21M-$3.63-2.21Cassava SciencesN/AN/A-$24.34M-$1.50-1.50 Is KOD or SAVA more profitable? Cassava Sciences' return on equity of -87.72% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kodiak SciencesN/A -115.71% -54.17% Cassava Sciences N/A -87.72%-72.05% SummaryKodiak Sciences beats Cassava Sciences on 7 of the 11 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.31M$2.42B$5.48B$9.72BDividend YieldN/A1.78%4.59%4.13%P/E Ratio-1.5020.8629.7524.63Price / SalesN/A688.91454.25102.60Price / CashN/A23.6624.8427.99Price / Book0.745.208.605.76Net Income-$24.34M$31.61M$3.26B$264.95M7 Day Performance-1.75%-1.52%0.55%0.31%1 Month Performance5.63%0.24%1.41%0.14%1 Year Performance-89.70%5.39%36.52%22.83% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences2.7201 of 5 stars$2.25+3.2%$2.00-11.1%-90.0%$105.31MN/A-1.5030Upcoming EarningsKODKodiak Sciences3.3017 of 5 stars$8.03+1.6%$9.00+12.1%+223.8%$423.66MN/A-2.2190News CoverageUpcoming EarningsKMDAKamada4.512 of 5 stars$7.34+3.1%$13.00+77.1%+28.8%$422.09M$167.24M25.31360News CoveragePositive NewsUpcoming EarningsERASErasca2.4318 of 5 stars$1.48+5.7%$4.57+208.9%-41.7%$419.27MN/A-2.39120Gap UpCGEMCullinan Therapeutics1.8028 of 5 stars$7.09-2.9%$30.00+323.1%-56.5%$418.42MN/A-2.2030News CoverageEarnings ReportAnalyst RevisionCMPSCOMPASS Pathways2.7831 of 5 stars$4.34-1.1%$16.29+275.2%-37.8%$416.38MN/A-2.36120PRTAProthena3.2388 of 5 stars$7.67-0.3%$30.25+294.4%-62.6%$412.88M$10.34M-1.36130Earnings ReportAnalyst RevisionTECXTectonic Therapeutic1.9634 of 5 stars$22.11-0.9%$80.33+263.3%+38.3%$412.86MN/A-5.47120News CoverageEarnings ReportUpcoming EarningsPRTCPureTech Health1.407 of 5 stars$17.15-0.6%$45.00+162.4%-19.2%$412.03M$4.32M0.00100CYRXCryoPort3.8241 of 5 stars$8.09+7.0%$12.00+48.3%-8.1%$405.63M$228.38M6.081,186Earnings ReportAnalyst RevisionGOSSGossamer Bio3.7913 of 5 stars$1.73-1.5%$8.50+390.5%+122.4%$394.05M$114.70M-2.80180News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionGap Up Related Companies and Tools Related Companies Kodiak Sciences Competitors Kamada Competitors Erasca Competitors Cullinan Therapeutics Competitors COMPASS Pathways Competitors Prothena Competitors Tectonic Therapeutic Competitors PureTech Health Competitors CryoPort Competitors Gossamer Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access